Interstitial lung abnormalities progression upon treatment with cabazitaxel for metastatic prostate cancer

Key Points

• To evaluate the progression of interstitial lung abnormalities in a patient receiving cabazitaxel for metastatic prostate cancer.
• Single case analysis of a 75-year-old patient with metastatic prostate cancer undergoing multiple therapies.
• Treatment regimen included cabazitaxel, docetaxel, abiraterone, olaparib, and radiotherapy with Ra223.
• Observed progression of interstitial lung abnormalities post cabazitaxel treatment.
• The patient's condition involved complex treatment history with other therapies prior to cabazitaxel.